Top Markets
Coin of the day
Marizyme, Inc. Marizyme, Inc.

Marizyme, Inc.

MRZM
株式のランク #41142
Marizyme, Inc. is a life sciences company primarily engaged in bringing... Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.
株価
$0.0003
最終同期: 2026-08-11
時価総額
$39.54K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Marizyme, Inc. (MRZM)

カテゴリー

Marizyme, Inc.(MRZM)の配当利回りの履歴
Marizyme, Inc.(銘柄コード: MRZM)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Marizyme, Inc.(MRZM)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)